<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Gerds AT</dc:creator>
  <dc:creator>Woo Ahn K</dc:creator>
  <dc:creator>Hu ZH</dc:creator>
  <dc:creator>Abdel-Azim H</dc:creator>
  <dc:creator>Akpek G</dc:creator>
  <dc:creator>Aljurf M</dc:creator>
  <dc:creator>Ballen KK</dc:creator>
  <dc:creator>Beitinjaneh A</dc:creator>
  <dc:creator>Bacher U</dc:creator>
  <dc:creator>Cahn JY</dc:creator>
  <dc:creator>Chhabra S</dc:creator>
  <dc:creator>Cutler C</dc:creator>
  <dc:creator>Daly A</dc:creator>
  <dc:creator>DeFilipp Z</dc:creator>
  <dc:creator>Gale RP</dc:creator>
  <dc:creator>Gergis U</dc:creator>
  <dc:creator>Grunwald MR</dc:creator>
  <dc:creator>Hale GA</dc:creator>
  <dc:creator>Hamilton BK</dc:creator>
  <dc:creator>Jagasia M</dc:creator>
  <dc:creator>Kamble RT</dc:creator>
  <dc:creator>Kindwall-Keller T</dc:creator>
  <dc:creator>Nishihori T</dc:creator>
  <dc:creator>Olsson RF</dc:creator>
  <dc:creator>Ramanathan M</dc:creator>
  <dc:creator>Saad AA</dc:creator>
  <dc:creator>Solh M</dc:creator>
  <dc:creator>Ustun C</dc:creator>
  <dc:creator>Valcárcel D</dc:creator>
  <dc:creator>Warlick E</dc:creator>
  <dc:creator>Wirk BM</dc:creator>
  <dc:creator>Kalaycio M</dc:creator>
  <dc:creator>Alyea E</dc:creator>
  <dc:creator>Popat U</dc:creator>
  <dc:creator>Sobecks R</dc:creator>
  <dc:creator>Saber W</dc:creator>
  <dc:date>2017</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">For patients with hematologic malignancies undergoing allogeneic hematopoietic cell transplantation, umbilical cord blood transplantation (UCBT) has become an acceptable alternative donor source in the absence of a matched sibling or unrelated donor. To date, however, there have been few published series dedicated solely to describing the outcomes of adult patients with myelodysplastic syndrome (MDS) who have undergone UCBT. Between 2004 and 2013, 176 adults with MDS underwent UCBT as reported to the Center for International Blood and Marrow Transplant Research. Median age at the time of transplantation was 56 years (range, 18-73 years). The study group included 10% with very low, 23% with low, 19% with intermediate, 19% with high, and 13% with very high-risk Revised International Prognostic Scoring System (IPSS-R) scores. The 100-day probability of grade II-IV acute graft-versus-host disease (GVHD) was 38%, and the 3-year probability of chronic GVHD was 28%. The probabilities of relapse and transplantation-related mortality (TRM) at 3 years were 32% and 40%, respectively, leading to a 3-year disease-free survival (DFS) of 28% and an overall survival (OS) of 31%. In multivariate analysis, increasing IPSS-R score at the time of HCT was associated with inferior TRM (P = .0056), DFS (P = .018), and OS (P = .0082), but not with GVHD or relapse. The presence of pretransplantation comorbidities was associated with TRM (P = .001), DFS (P = .02), and OS (P = .001). Reduced-intensity conditioning was associated with increased risk of relapse (relative risk, 3.95; 95% confidence interval, 1.78-8.75; P &lt; .001), and although a higher proportion of myeloablative UCBTs were performed in patients with high-risk disease, the effect of conditioning regimen intensity was the same regardless of IPSS-R score. For some individuals who lack a matched sibling or unrelated donor, UCBT can result in long-term DFS; however, the success of UCBT in this population is hampered by a high rate of TRM.</dc:description>
  <dc:format>application/pdf</dc:format>
  <dc:identifier>https://sonar.ch/global/documents/185141</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1016/j.bbmt.2017.03.014</dc:relation>
  <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/28288952</dc:relation>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:source>Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. - 2017</dc:source>
  <dc:subject xmlns:ns1="xml" ns1:lang="en">Blood and marrow transplantation</dc:subject>
  <dc:subject xmlns:ns2="xml" ns2:lang="en">Myelodysplastic syndrome</dc:subject>
  <dc:subject xmlns:ns3="xml" ns3:lang="en">Umbilical cord transplantation</dc:subject>
  <dc:subject xmlns:ns4="xml" ns4:lang="en">Adolescent</dc:subject>
  <dc:subject xmlns:ns5="xml" ns5:lang="en">Adult</dc:subject>
  <dc:subject xmlns:ns6="xml" ns6:lang="en">Aged</dc:subject>
  <dc:subject xmlns:ns7="xml" ns7:lang="en">Cord Blood Stem Cell Transplantation</dc:subject>
  <dc:subject xmlns:ns8="xml" ns8:lang="en">Graft vs Host Disease</dc:subject>
  <dc:subject xmlns:ns9="xml" ns9:lang="en">Humans</dc:subject>
  <dc:subject xmlns:ns10="xml" ns10:lang="en">Middle Aged</dc:subject>
  <dc:subject xmlns:ns11="xml" ns11:lang="en">Myelodysplastic Syndromes</dc:subject>
  <dc:subject xmlns:ns12="xml" ns12:lang="en">Probability</dc:subject>
  <dc:subject xmlns:ns13="xml" ns13:lang="en">Recurrence</dc:subject>
  <dc:subject xmlns:ns14="xml" ns14:lang="en">Risk Assessment</dc:subject>
  <dc:subject xmlns:ns15="xml" ns15:lang="en">Survival Analysis</dc:subject>
  <dc:subject xmlns:ns16="xml" ns16:lang="en">Transplantation Conditioning</dc:subject>
  <dc:subject xmlns:ns17="xml" ns17:lang="en">Treatment Outcome</dc:subject>
  <dc:subject xmlns:ns18="xml" ns18:lang="en">Young Adult</dc:subject>
  <dc:title xmlns:ns19="xml" ns19:lang="en">Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes.</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
